TRAIL, caspases and maturation of normal and leukemic myeloid precursors

Leukemia and Lymphoma

Volumn 47, Issue 8, 2006, Pages 1459-1468

  Corallini, Federica ^a   Milani, Daniela ^a   Nicolin, Vanessa ^b   Secchiero, Paola ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Caspases; Hemopoiesis; Myeloid cells; TRAIL

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE; CASPASE 8 INHIBITOR; CASPASE 9 INHIBITOR; COLECALCIFEROL; COLONY STIMULATING FACTOR 1; CYTARABINE; CYTOKINE; DAUNORUBICIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FLICE INHIBITORY PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; PARTHENOLIDE; RETINOIC ACID; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW CELL; CELL LINEAGE; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; ENZYME INHIBITION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MYELOID LEUKEMIA; MYELOID PROGENITOR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; CASPASES; HEMATOPOIESIS; HUMANS; MYELOID PROGENITOR CELLS; NEOPLASTIC STEM CELLS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR STEM CELLS;

EID: 33748560475     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190500513611     Document Type: Review

References (111)

1. Heissig, B and Ohki, Y and Sato, Y and Rafii, S and Werb, Z and Hattori, K. (2005) A role for niches in hematopoietic cell development Hematology, 10, pp. 247-253.
2. Park, J. (1996) Cytokine regulation of apoptosis in hematopoietic precursor cells Curr Opin Hematol, 3, pp. 191-196.
3. Cantor, A and Orkin, S. (2002) Transcriptional regulation of erythropoiesis: An affair involving multiple partners Oncogene, 21, pp. 3368-3376.
4. Perry, C and Soreq, H. (2002) Transcriptional regulation of erythropoiesis. Fine tuning of combinatorial multi-domain elements Eur J Biochem, 269, pp. 3607-3618.
5. Skalnik, D. (2002) Transcriptional mechanisms regulating myeloid-specific genes Gene, 284, pp. 1-21.
6. Wiley, S and Schooley, K and Smolak, P and Din, W and Huang, C and Nicholl, J and (1995) Identification and characterization of a new member of the TNF family that induces apoptosis Immunity, 3, pp. 673-682.
7. De Maria, R and Zeuner, A and Eramo, A and Domenichelli, C and Bonci, D and Grignani, F and (1999) Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1 Nature, 401, pp. 489-493.
8. Zamai, L and Secchiero, P and Pierpaoli, S and Bassini, A and Papa, S and Alnemri, E and (2000) TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis Blood, 95, pp. 3716-3724.
9. Secchiero, P and Melloni, E and Heikinheimo, M and Mannisto, S and Di Pietro, R and Iacone, A and (2004) TRAIL regulates normal erythroid maturation through an ERK-dependent pathway Blood, 103, pp. 517-522.
10. Mirandola, P and Gobbi, G and Ponti, C and Sponzilli, I and Cocco, L and Vitale, M. (2005) PKC{epsilon} controls the protection against TRAIL in erythroid progenitors Blood. [Epub ahead of print]
11. Crist, S and Elzey, B and Ludwig, A and Griffith, T and Staack, J and Lentz, S and (2004) Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megakaryocytes and platelets Exp Hematol, 32, pp. 1073-1081.
12. Melloni, E and Secchiero, P and Celeghini, C and Campioni, D and Grill, V and Guidotti, L and (2005) Functional expression of TRAIL and TRAIL-R2 during human megakaryocytic development J Cell Physiol, 204, pp. 975-982.
13. Secchiero, P and Gonelli, A and Mirandola, P and Melloni, E and Zamai, L and Celeghini, C and (2002) Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway Blood, 100, pp. 2421-2429.
14. Secchiero, P and Milani, D and Gonelli, A and Melloni, E and Campioni, D and Gibellini, D and (2003) Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells J Leukoc Biol, 74, pp. 223-232.
15. Pitti, R and Marsters, S and Ruppert, S and Donahue, C and Moore, A and Ashkenazi, A. (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family J Biol Chem, 271, pp. 12687-12690.
16. Almasan, A and Ashkenazi, A. (2003) Apo2L/TRAIL: Apoptosis signaling, biology, and potential for cancer therapy Cytokine Growth Factor Rev, 14, pp. 337-348.
17. Mariani, S and Krammer, P. (1998) Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage Eur J Immunol, 28, pp. 973-982.
18. Liabakk, N and Sundan, A and Torp, S and Aukrust, P and Froland, S and Espevik, T. (2002) Development, characterization and use of monoclonal antibodies against sTRAIL: Measurement of sTRAIL by ELISA J Immunol Methods, 259, pp. 119-128.
19. Gruss, H. (1996) Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily Int J Clin Lab Res, 26, pp. 143-159.
20. Pan, G and O'Rourke, K and Chinnaiyan, A and Gentz, R and Ebner, R and Ni, J and (1997) The receptor for the cytotoxic ligand TRAIL Science, 276, pp. 111-113.
21. Hymowitz, S and Ultsch, M and Hurst, A and Totpal, K and Ashkenazi, A and De Vos, A and (2000) A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL Biochemistry, 39, pp. 633-640.
22. Di Pietro, R and Zauli, G. (2004) Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L J Cell Physiol, 201, pp. 331-340.
23. Ashkenazi, A and Pai, R and Fong, S and Leung, S and Lawrence, D and Marsters, S and (1999) Safety and anti tumor activity of recombinant soluble Apo2 ligand J Clin Investig, 104, pp. 155-162.
24. Walczak, H and Miller, R and Ariail, K and Gliniak, B and Griffith, T and Kubin, M and (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nat Med, 5, pp. 157-163.
25. Bouralexis, S and Findlay, D and Evdokiou, A. (2005) Death to the bad guys: Targeting cancer via Apo2L/TRAIL Apoptosis, 10, pp. 35-51.
26. Secchiero, P and Vaccarezza, M and Gonelli, A and Zauli, G. (2004) TNF-related apoptosis-inducing ligand (TRAIL): A potential candidate for combined treatment of hematological malignancies Curr Pharm Des, 10, pp. 3673-3681.
27. Plasilova, M and Zivny, J and Jelinek, J and Neuwirtova, R and Cermak, J and Necas, E and (2002) TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors Leukemia, 16, pp. 67-73.
28. Jones, D and Ganeshaguru, K and Mitchell, W and Foroni, L and Baker, R and Prentice, H and (2003) Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand Br J Haematol, 121, pp. 713-720.
29. Insinga, A and Monestiroli, S and Ronzoni, S and Gelmetti, V and Marchesi, F and Viale, A and (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway Nat Med, 11, pp. 71-76.
30. Nebbioso, A and Clarke, N and Voltz, E and Germain, E and Ambrosino, C and Bontempo, P and (2005) Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells Nat Med, 11, pp. 77-84.
31. Zang, D and Goodwin, R and Loken, M and Bryant, E and Deeg, H. (2001) Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: Effects on in vitro hemopoiesis Blood, 98, pp. 3058-3065.
32. Uno, K and Inukai, T and Kayagaki, N and Goi, K and Sato, H and Nemoto, A and (2003) TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells Blood, 101, pp. 3658-3667.
33. Gazitt, Y. (1999) TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells Leukemia, 13, pp. 1817-1824.
34. Gazitt, Y and Shaughnessy, P and Montgomery, W. (1999) Apoptosis-induced by TRAIL and TNF-alpha in human multiple myeloma cells is not blocked by BCL-2 Cytokine, 11, pp. 1010-1019.
35. Liu, Q and El-Deiry, W and Gazitt, Y. (2001) Additive effect of Apo2L/ TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines Exp Hematol, 29, pp. 962-970.
36. Spencer, A and Yeh, S and Koutrevelis, K and Baulch-Brown, C. (2002) TRAIL-induced apoptosis of authentic myeloma cells does not correlate with the procaspase-8/cFLIP ratio Blood, 100, pp. 3049.
37. Fandy, T and Shankar, S and Ross, D and Sausville, E and Srivastava, R. (2005) Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma Neoplasia, 7, pp. 646-657.
38. Sheridan, J and Marsters, S and Pitti, R and Gurney, A and Skubatch, M and Baldwin, D and (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors Science, 277, pp. 818-821.
39. Ashkenazi, A. (2002) Targeting death and decoy receptors of the tumour necrosis factor superfamily Nat Rev Cancer, 2, pp. 420-430.
40. Kimberley, F and Screaton, G. (2004) Following a TRAIL: Update on a ligand and its five receptors Cell Res, 14, pp. 359-372.
41. Chaudhary, P and Eby, M and Jasmin, A and Bookwalter, A and Murray, J and Hood, L. (1997) Death receptor 5, a new member of the TNFR family, and DR4 induce FADD- dependent apoptosis and activate the NF-kappaB pathway Immunity, 7, pp. 821-830.
42. MacFarlane, M and Ahmad, M and Srinivasula, S and Fernandes-Alnemri, T and Cohen, G and Alnemri, E. (1997) Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL J Biol Chem, 272, pp. 25417-25420.
43. Screaton, G and Mongkolsapaya, J and Xu, X and Cowper, A and McMichael, A and Bell, J. (1997) TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL Curr Biol, 7, pp. 693-696.
44. Walczak, H and Degli-Esposti, M and Johnson, R and Smolak, P and Waugh, J and Boiani, N and (1997) TRAILR2: A novel apoptosis-mediating receptor for TRAIL Embo J, 16, pp. 5386-5397.
45. Wu, G and Burns, T and McDonald, E and Jiang, W and Meng, R and Krantz, I and (1997) KILLER/DR5 is a DNA damage-inducible p53 regulated death receptor gene Nat Genet, 17, pp. 141-143.
46. Degli-Esposti, M and Smolak, P and Walczak, H and Waugh, J and Huang, C and DuBose, R and (1997) Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family J Exp Med, 186, pp. 1165-1170.
47. Pan, G and Ni, J and Yu, G and Wei, Y and Dixit, V. (1998) TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signaling FEBS Lett, 424, pp. 41-45.
48. Marsters, S and Sheridan, J and Pitti, R and Huang, A and Skubatch, M and Baldwin, D and (1997) A novel receptor for Apo2L/TRAIL contains a truncated death domain Curr Biol, 7, pp. 1003-1006.
49. Degli-Esposti, M and Dougall, W and Smolak, P and Waugh, J and Smith, C and Goodwin, R. (1997) The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain Immunity, 7, pp. 813-820.
50. Sheikh, M and Fornace, A, Jr. (2000) Death and decoy receptors and p53-mediated apoptosis Leukemia, 14, pp. 1509-1513.
51. Ozoren, N and El-Deiry, W. (2003) Cell surface death receptor signaling in normal and cancer cells Semin Cancer Biol, 13, pp. 135-147.
52. Sheikh, M and Huang, Y and Fernandez-Salas, E and El-Deiry, W and Friess, H and Amundson, S and (1999) The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract Oncogene, 18, pp. 4153-4159.
53. Meng, R and McDonald, E and Sheikh, M and Fornace, A, Jr and El-Deiry, W. (2000) The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/ DR5-dependent colon cancer apoptosis Mol Ther, 1, pp. 130-144.
54. Ruiz de Almodovar, C and Ruiz-Ruiz, C and Rodriguez, A and Ortiz-Ferron, G and Redondo, J and Lopez-Rivas, A. (2004) TRAIL decoy receptor TRAIL-R3 is upregulated by p53 in breast tumor cells through a mechanism involving an intronic p53 binding site J Biol Chem, 279, pp. 4093-4101.
55. Emery, J and McDonnell, P and Burke, M and Deen, K and Lyn, S and Silverman, C and (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL J Biol Chem, 273, pp. 14363-14367.
56. Truneh, A and Sharma, S and Silverman, C and Khandekar, S and Reddy, M and Deen, K and (2000) Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor J Biol Chem, 275, pp. 23319-23325.
57. Holen, I and Croucher, P and Hamdy, F and Eaton, C. (2002) Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells Cancer Res, 62, pp. 1619-1623.
58. Miyashita, T and Kawakami, A and Nakashima, T and Yamasaki, S and Tamai, M and Tanaka, F and (2004) Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells Clin Exp Immunol, 137, pp. 430-436.
59. Kim, K and Fisher, M and Xu, S and el-Deiry, W. (2000) Molecular determinants of response to TRAIL in killing of normal and cancer cells Clin Cancer Res, 6, pp. 335-346.
60. Pan, G and Ni, J and Wei, Y and Yu, G and Gentz, R and Dixit, V. (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL Science, 277, pp. 815-818.
61. Mongkolsapaya, J and Cowper, A and Xu, X and Morris, G and McMichael, A and Bell, J and (1998) Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): A new receptor protecting lymphocytes from the death ligand TRAIL J Immunol, 160, pp. 3-6.
62. Wuchter, C and Krappmann, D and Cai, Z and Ruppert, V and Scheidereit, C and Dorken, B and (2001) In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kB activity Leukemia, 15, pp. 921-928.
63. Lincz, L and Yeh, T and Spencer, A. (2001) TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy Leukemia, 15, pp. 1650-1657.
64. Secchiero, P and Gonelli, A and Carnevale, E and Milani, D and Pandolfi, A and Zella, D and (2003) TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways Circulation, 107, pp. 2250-2256.
65. Secchiero, P and Zerbinati, C and Rimondi, E and Corallini, F and Milani, D and Grill, V and (2004) TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells Cell Mol Life Sci 61, pp. 1965-1974.
66. Mirandola, P and Ponti, C and Gobbi, G and Sponzilli, I and Vaccarezza, M and Cocco, L and (2004) Activated human NK and CD8 + T cells express both TNF-related apoptosis inducing ligand (TRAIL) and TRAIL receptors, but are resistant to TRAIL-mediated cytotoxicity Blood, 104, pp. 2418-2424.
67. Secchiero, P and Tiribelli, M and Barbarotto, E and Celeghini, C and Michelutti, A and Masolini, P and (2005) Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells J Cell Physiol, 205, pp. 246-252.
68. Griffith, T and Chin, W and Jackson, G and Lynch, D and Kubin, M. (1998) Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells J Immunol, 161, pp. 2833-2840.
69. Zhang, X and Franco, A and Myers, K and Gray, C and Nguyen, T and Hersey, P. (1999) Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma Cancer Res, 59, pp. 2747-2753.
70. Chinnaiyan, A and O'Rourke, K and Tewari, M and Dixit, V. (1995) FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis Cell, 81, pp. 505-512.
71. Boldin, M and Mett, I and Varfolomeev, E and Chumakov, I and Shemer-Avni, Y and Camonis, J and (1995) Self-association of the "death domains" of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects J Biol Chem, 270, pp. 387-391.
72. Kischkel, F and Lawrence, D and Tinel, A and LeBlanc, H and Virmani, A and Schow, P and (2001) Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8 J Biol Chem, 276, pp. 46639-46646.
73. Muhlenbeck, F and Haas, E and Schwenzer, R and Schubert, G and Grell, M and Smith, C and (1998) TRAIL/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways J Biol Chem, 273, pp. 33091-33098.
74. Herr, I and Wilhelm, D and Meyer, E and Jeremias, I and Angel, P and Debatin, K. (1999) JNK/SAPK activity contributes to TRAIL-induced apoptosis Cell Death Differ, 6, pp. 130-135.
75. Wachter, T and Sprick, M and Hausmann, D and Kerstan, A and McPherson, K and Stassi, G and (2004) cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes J Biol Chem, 279, pp. 52824-52834.
76. Ricci, M and Jin, Z and Dews, M and Yu, D and Thomas-Tikhonenko, A and Dicker, D and (2004) Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity Mol Cell Biol, 24, pp. 8541-8555.
77. Sharp, D and Lawrence, D and Ashkenazi, A. (2005) Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis J Biol Chem, 280, pp. 19401-19409.
78. Sprick, M and Walczak, H. (2004) The interplay between the Bcl-2 family and death receptor-mediated apoptosis Biochim Biophys Acta, 1644, pp. 125-132.
79. Harper, N and Farrow, S and Kaptein, A and Cohen, G and MacFarlane, M. (2001) Modulation of tumor necrosis factor apoptosis-inducing ligand-induced NF-kappaB activation by inhibition of apical caspases J Biol Chem, 276, pp. 34743-34752.
80. Zauli, G and Pandolfi, A and Gonelli, A and Di Pietro, R and Guarnieri, S and Ciabattoni, G and (2003) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells Circ Res, 92, pp. 732-740.
81. Hu, W and Johnson, H and Shu, H. (1999) Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways J Biol Chem, 274, pp. 30603-30610.
82. Campioni, D and Secchiero, P and Corallini, F and Melloni, E and Capitani, S and Lanza, F and (2005) Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes Am J Pathol, 166, pp. 557-563.
83. Schmidt, U and van den Akker, E and Parren-van Amelsvoort, M and Litos, G and De Bruijn, M and Gutierrez, L and (2004) Btk is required for an efficient response to erythropoietin and for SCF-controlled protection against TRAIL in erythroid cells J Exp Med, 199, pp. 785-795.
84. Silvestris, F and Cafforio, P and Tucci, M and Dammacco, F. (2002) Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: A major pathogenetic mechanism of anemia in multiple myeloma Blood, 99, pp. 1305-1313.
85. Miyazaki, R and Ogata, H and Kobayashi, Y. (2001) Requirement of thrombopoietin-induced activation of ERK for megakaryocyte differentiation and of p38 for erythroid differentiation Ann Hematol, 80, pp. 284-291.
86. Choi, J. (2005) Relationships between tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and hematopoietic activity in healthy adults Ann Hematol, 84, pp. 728-733.
87. Kawamoto, H and Minato, N. (2004) Myeloid cells Int J Bioch Cell Biol, 36, pp. 1374-1379.
88. Ferrari, S and Tagliafico, E and Ceccherelli, G and Selleri, L and Calabretta, B and Donelli, A and (1989) Expression of the myeloperoxidase gene in acute and chronic myeloid leukemias: relationship to the expression of cell cycle-related genes Leukemia, 3, pp. 423-430.
89. Schwaller, J and Pabst, T and Koeffler, H and Niklaus, G and Loetscher, P and Fey, M and (1997) Expression and regulation of G1 cell-cycle inhibitors (p16INK4A, p15INK4B, p18INK4C, p19INK4D) in human acute myeloid leukemia and normal myeloid cells Leukemia, 11, pp. 54-63.
90. Bennett, J and Catovsky, D and Daniel, M and Flandrin, G and Galton, D and Gralnick, H and (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group Br J Haematol, 33, pp. 451-458.
91. Drexler, H. (1987) Classification of acute myeloid leukemias: A comparison of FAB and immunophenotyping Leukemia, 1, pp. 697-705.
92. Ferrari, S and Grande, A and Manfredini, R and Tagliafico, E and Zucchini, P and Torelli, G and (1993) Expression of interleukins 1, 3, 6, stem cell factor and their receptors in acute leukemia blast cells and in normal peripheral lymphocytes and monocytes Eur J Haematol, 50, pp. 141-148.
93. Ferrari, S and Grande, A and Zucchini, P and Manfredini, R and Tagliafico, E and Rossi, E and (1993) Overexpression of c-kit in a leukemic cell population carrying a trisomy 4 and its relationship with the proliferative capacity Leuk Lymphoma, 9, pp. 495-501.
94. Olsson, I and Bergh, G and Ehinger, M and Gullberg, U. (1996) Cell differentiation in acute myeloid leukemia Eur J Haematol, 57, pp. 1-16.
95. Irvine, A and Berney, J and Francis, G. (1990) Dissociation of the proliferation and differentiation stimuli of granulocyte colony-stimulating factor (G-CSF) Leukemia, 4, pp. 203-209.
96. Castaigne, S and Chomienne, C and Daniel, M and Ballerini, P and Berger, R and Fenaux, P and (1990) All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia: Clinical results Blood, 76, pp. 1704-1709.
97. Chomienne, C and Fenaux, P and Degos, L. (1996) Retinoid differentiation therapy in promyelocytic leukemia FASEB J, 10, pp. 1025-1030.
98. Collins, S. (1987) The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression Blood, 70, pp. 1233-1244.
99. Sokoloski, J and Hodnick, W and Mayne, S and Cinquina, C and Kim, C and Sartorelli, A. (1997) Induction of the differentiation of HL-60 promyelocytic leukemia cells by vitamin E and other antioxidants in combination with low levels of vitamin D3: Possible relationship to NF-kappa B Leukemia, 11, pp. 1546-1553.
100. Medupalli, A and Li, Z and Hromchak, R and Bloch, A. (2001) NF-kappaB (p65/RelA) as a regulator of TNF alpha-mediated ML-1 cell differentiation Leukemia, 15, pp. 808-813.
101. Richter, G and Hayden-Ledbetter, M and Irgang, M and Ledbetter, J and Westermann, J and Korner, I and (2001) Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34(+) progenitor cells during differentiation into antigen presenting cells J Biol Chem, 276, pp. 45686-45693.
102. Berry, D and Clark, C and Meckling-Gill, K. (2002) 1α,25-dihydroxyvitamin D3 stimulates phosphorylation of IκBα and synergizes with TPA to induce nuclear translocation of NFκB during monocytic differentiation of NB4 leukemia cells Exp Cell Res, 272, pp. 176-184.
103. Wang, J and Lenardo, M. (2000) Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies J Cell Sci, 113, pp. 753-757.
104. Zermati, Y and Garrido, C and Amsellem, S and Fishelson, S and Bouscary, D and Valensi, F and (2001) Caspase activation is required for terminal erythroid differentiation J Exp Med, 193, pp. 247-254.
105. Alam, A and Cohen, L and Aouad, S and Sekaly, R. (1999) Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells J Exp Med, 190, pp. 1879-1890.
106. Kennedy, N and Kataoka, T and Tschopp, J and Budd, R. (1999) Caspase activation is required for T cell proliferation J Exp Med, 190, pp. 1891-1895.
107. Chun, H and Zheng, L and Ahmad, M and Wang, J and Speirs, C and Siegel, R and (2002) Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency Nature, 419, pp. 395-399.
108. Trauzold, A and Wermann, H and Arlt, A and Schutze, S and Schafer, H and Oestern, S and (2001) CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells Oncogene, 20, pp. 4258-4269.
109. Chaudhary, P and Eby, M and Jasmin, A and Kumar, A and Liu, L and Hood, L. (2000) Activation of the NF-kB pathway by caspase 8 and its homologs Oncogene, 19, pp. 4451-4460.
110. Hu, W and Johnson, H and Shu, H. (2000) Activation of NF-kB by FADD, casper, and caspase 8 J Biol Chem, 275, pp. 10838-10844.
111. Rathore, N and Matta, H and Chaudhary, P. (2004) An evolutionary conserved pathway of nuclear factor-kappaB activation involving caspase-mediated cleavage and N-end rule pathway-mediated degradation of IkappaBalpha J Biol Chem, 279, pp. 39358-39365.